+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers



Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers



Vaccine 16(8): 810-817



The efficacy of recombinant Bacillus anthracis Protective Antigen (rPA) produced in Bacillus subtilis and formulated in Alhydrogel or MPL-TDM-CWS (Ribi adjuvant) has been tested and compared to the licensed UK human vaccine in guinea pigs challenged by the aerosol route with the Ames strain of B. anthracis. rPA combined with the Ribi adjuvant was found to be the only formulation to provide 100% protection from challenge. Analysis of immunological parameters in the individual animals revealed significant differences between the rPA/Ribi vaccine group and rPA/Alhydrogel and human vaccine groups for antigen specific lymphocyte proliferation, PA neutralisation and antigen specific IgG2 levels, but indicated no significant differences in PA-specific IgG1 levels. rPA formulated in Alhydrogel induced a mainly IgG1 response whilst the rPA/Ribi vaccine produced a predominantly IgG2 response.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009265324

Download citation: RISBibTeXText

PMID: 9627938

DOI: 10.1016/s0264-410x(97)00268-5


Related references

Production and purification of recombinant protective antigen and protective efficacy against Bacillus anthracis. Letters in Applied Microbiology 26(1): 56-60, 1998

Comparative vaccine efficacy of different isoforms of recombinant protective antigen against Bacillus anthracis spore challenge in rabbits. Vaccine 24(17): 3469-3476, 2006

Recombinant GroEL enhances protective antigen-mediated protection against Bacillus anthracis spore challenge. Medical Microbiology and Immunology 202(2): 153-165, 2013

Contribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccine. Infection and Immunity 72(6): 3471-3477, 2004

Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infection and Immunity 74(1): 394-398, 2006

Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infection and Immunity 75(8): 4020-4029, 2007

A therapeutic human antibody against the domain 4 of the Bacillus anthracis protective antigen shows protective efficacy in a mouse model. Biochemical and Biophysical Research Communications 509(2): 611-616, 2019

Protective Immune Response against Bacillus anthracis Induced by Intranasal Introduction of a Recombinant Adenovirus Expressing the Protective Antigen Fused to the Fc-fragment of IgG2a. Acta Naturae 6(1): 76-84, 2014

Experimental anthrax vaccines: Efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13(18): 1779-1784, 1995

Studies on infection with Bacillus anthracis III Chemical and immunological properties of the protective antigen in crude extracts of skin lesions of B anthracis. Journal of Infectious Diseases 80(1): 28-40, 1947

A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Vaccine 24(10): 1501-1514, 2006

Immunological characterisation of protective antigen (PA) of Bacillus anthracis. Indian Veterinary Journal 70(8): 691-694, 1993

Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen. Infection and Immunity 74(1): 794-797, 2006

Immunogenicity of recombinant Bacillus strains with a cloned gene for synthesis of the protective antigen of Bacillus anthracis. Molecular Genetics, Microbiology and Virology 22(3): 103-111, 2007

Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis. Molekuliarnaia Genetika Mikrobiologiia i Virusologiia 2007(3): 15-21, 2007